TD Ameritrade Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

TD Ameritrade Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6	Closed	-$1K	–	672
2021 Q1	$1K	Hold	6	–	–	﹤0.01%	614
2020 Q4	$1K	Buy	+6	New	+$889	﹤0.01%	614
2019 Q3	–	Sell	-13	Closed	-$2K	–	714
2019 Q2	$2K	Hold	13	–	–	﹤0.01%	579
2019 Q1	$2K	Sell	13 -36	-73%	-$4.63K	﹤0.01%	530
2018 Q4	$5K	Buy	49 +31	+172%	+$3.88K	﹤0.01%	453
2018 Q3	$3K	Buy	18 +3	+20%	+$410	﹤0.01%	466
2018 Q2	$2K	Buy	+15	New	+$1.42K	﹤0.01%	376

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TD Ameritrade Investment Management's SRPT Position: Q2 2021 in Review

TD Ameritrade Investment Management sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 6 shares — an estimated $1K sold.

TD Ameritrade Investment Management first reported a position in SRPT in Q2 2018 and held it in 7 quarters. The position peaked at $5K in Q4 2018. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

TD Ameritrade Investment Management reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
TD Ameritrade Investment Management sold 6 Sarepta Therapeutics shares in Q2 2021, an estimated $1K.
TD Ameritrade Investment Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 7 quarters.
TD Ameritrade Investment Management's Sarepta Therapeutics position peaked at $5K in Q4 2018.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on TD Ameritrade Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.